| scholarly article | Q13442814 |
| P50 | author | Marylyn Addo | Q66714025 |
| Marcus Altfeld | Q72531060 | ||
| Daniel E Kaufmann | Q87677945 | ||
| Eric S Rosenberg | Q89548046 | ||
| Mathias Lichterfeld | Q91496240 | ||
| Elizabeth T Kalife | Q114576937 | ||
| Daryld A Strick | Q114576938 | ||
| Bruce D. Walker | Q23770361 | ||
| P2093 | author name string | Mary N Johnston | |
| Bradford S Wagner | |||
| Paul K Lee | |||
| P2860 | cites work | Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene | Q56591978 |
| Contrasting Genetic Influence of CCR2 and CCR5 Variants on HIV-1 Infection and Disease Progression | Q56607621 | ||
| The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection | Q56791550 | ||
| Control of HIV despite the Discontinuation of Antiretroviral Therapy | Q56851967 | ||
| Evolution and transmission of stable CTL escape mutations in HIV infection | Q56880602 | ||
| Immune control of HIV-1 after early treatment of acute infection | Q56961920 | ||
| Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes | Q57075675 | ||
| Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia | Q57075698 | ||
| Control of SIV rebound through structured treatment interruptions during early infection | Q57146531 | ||
| The rate of CD4 decline as a determinant of progression to AIDS independent of the most recent CD4 count | Q57181542 | ||
| HIV-1 specific CD8+ T cells with an effector phenotype and control of viral replication | Q61941182 | ||
| Augmentation of HIV-1-specific T helper cell responses in chronic HIV-1 infection by therapeutic immunization | Q73558299 | ||
| HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors | Q78342521 | ||
| Presence of HIV-1 Gag-specific IFN-gamma+IL-2+ and CD28+IL-2+ CD4 T cell responses is associated with nonprogression in HIV-1 infection | Q78551235 | ||
| Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial | Q79946492 | ||
| Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection | Q24536249 | ||
| HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors | Q24676982 | ||
| Lineage relationship and protective immunity of memory CD8 T cell subsets | Q28206693 | ||
| Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia | Q28254584 | ||
| Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators | Q29547281 | ||
| Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection | Q29614956 | ||
| Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy | Q29615992 | ||
| A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression | Q33604871 | ||
| Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection | Q33869806 | ||
| Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects | Q33949316 | ||
| High-level HIV-1 viremia suppresses viral antigen-specific CD4(+) T cell proliferation | Q33950164 | ||
| Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells | Q33981572 | ||
| Infection with GB virus C and reduced mortality among HIV-infected patients | Q34090499 | ||
| HIV chemotherapy | Q34223088 | ||
| Human immunodeficiency virus type 1 fitness is a determining factor in viral rebound and set point in chronic infection | Q34227596 | ||
| Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. | Q34468117 | ||
| Lymphocyte proliferative responses to human immunodeficiency virus antigens in vitro | Q34570241 | ||
| Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy | Q34789249 | ||
| The functional CD8 T cell response to HIV becomes type-specific in progressive disease | Q34815358 | ||
| Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment | Q34857689 | ||
| Enhanced detection of human immunodeficiency virus type 1-specific T-cell responses to highly variable regions by using peptides based on autologous virus sequences | Q35149407 | ||
| Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. | Q36369035 | ||
| HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity | Q36371562 | ||
| Diminished Proliferation of Human Immunodeficiency Virus-Specific CD4+T Cells Is Associated with Diminished Interleukin-2 (IL-2) Production and Is Recovered by Exogenous IL-2 | Q36474240 | ||
| Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection | Q36889122 | ||
| Persistent recognition of autologous virus by high-avidity CD8 T cells in chronic, progressive human immunodeficiency virus type 1 infection. | Q36943282 | ||
| Infection with Multiple Human Immunodeficiency Virus Type 1 Variants Is Associated with Faster Disease Progression | Q37059806 | ||
| Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection | Q39601164 | ||
| Predictors of Plasma Human Immunodeficiency Virus Type 1 RNA Control after Discontinuation of Highly Active Antiretroviral Therapy Initiated at Acute Infection Combined with Structured Treatment Interruptions and Immune‐Based Therapies | Q40548790 | ||
| A controlled trial of granulocyte macrophage-colony stimulating factor during interruption of HAART. | Q40556224 | ||
| Reduced antiretroviral drug susceptibility among patients with primary HIV infection | Q41692662 | ||
| Impact of hepatitis G virus co-infection on the course of hepatitis C virus infection before and after liver transplantation | Q42991527 | ||
| Effect of coinfection with GB virus C on survival among patients with HIV infection | Q43034157 | ||
| Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection | Q43542210 | ||
| A prospective trial of structured treatment interruptions in human immunodeficiency virus infection | Q44767301 | ||
| Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy | Q45721932 | ||
| Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus | Q45722048 | ||
| HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus | Q45729968 | ||
| Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in human immunodeficiency virus-infected patients: implications for intermittent therapeutic strategies | Q45731190 | ||
| Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination | Q45731214 | ||
| Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption | Q45740983 | ||
| Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study | Q45743784 | ||
| Antiretroviral-drug resistance among patients recently infected with HIV. | Q46277555 | ||
| HIV evolution: CTL escape mutation and reversion after transmission | Q47211742 | ||
| Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point | Q47371942 | ||
| HIV-1-specific cytotoxicity is preferentially mediated by a subset of CD8(+) T cells producing both interferon-gamma and tumor necrosis factor-alpha | Q47835000 | ||
| Comparison of overlapping peptide sets for detection of antiviral CD8 and CD4 T cell responses | Q48002526 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | acute HIV infection | Q12777087 |
| P304 | page(s) | e36 | |
| P577 | publication date | 2004-11-01 | |
| P1433 | published in | PLOS MEDICINE | Q1686921 |
| P1476 | title | Limited durability of viral control following treated acute HIV infection | |
| P478 | volume | 1 |
| Q34662516 | A novel Acute Retroviral Syndrome Severity Score predicts the key surrogate markers for HIV-1 disease progression |
| Q35058440 | A stochastic multi-scale model of HIV-1 transmission for decision-making: application to a MSM population |
| Q57175535 | A study on the dynamics of temporary HIV treatment to assess the controversial outcomes of clinical trials: An in-silico approach |
| Q36859219 | Acute HIV infection: the impact of anti-retroviral treatment on cellular immune responses |
| Q51971392 | An IL-15 dependent CD8 T cell response to selected HIV epitopes is related to viral control in early-treated HIV-infected subjects. |
| Q28754733 | Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cells |
| Q33925025 | Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment |
| Q34693248 | Antiretroviral treatment of HIV infected adults |
| Q34539993 | Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases |
| Q36471285 | Attenuated disease in SIV-infected macaques treated with a monoclonal antibody against FasL. |
| Q35175897 | Augmented HIV-specific interferon-gamma responses, but impaired lymphoproliferation during interruption of antiretroviral treatment initiated in primary HIV infection |
| Q35115062 | CD4+ T-cell decline after the interruption of antiretroviral therapy in ACTG A5170 is predicted by differential expression of genes in the ras signaling pathway |
| Q92857870 | CD8+ T-Cell Response to HIV Infection in the Era of Antiretroviral Therapy |
| Q35784804 | Changes in paracrine interleukin-2 requirement, CCR7 expression, frequency, and cytokine secretion of human immunodeficiency virus-specific CD4+ T cells are a consequence of antigen load |
| Q37789343 | Clinical management of acute HIV infection: best practice remains unknown |
| Q34550802 | Compartmentalization of simian immunodeficiency virus replication within secondary lymphoid tissues of rhesus macaques is linked to disease stage and inversely related to localization of virus-specific CTL. |
| Q28766705 | Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection |
| Q28472597 | Control of viremia and prevention of AIDS following immunotherapy of SIV-infected macaques with peptide-pulsed blood |
| Q34045616 | De novo generation of escape variant-specific CD8+ T-cell responses following cytotoxic T-lymphocyte escape in chronic human immunodeficiency virus type 1 infection |
| Q38032363 | Developing strategies for HIV-1 eradication |
| Q28742727 | Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption |
| Q42645470 | Early treatment and HIV-1 reservoirs: a stitch in time? |
| Q42722482 | Epidemiologically linked transmission of HIV-1 illustrates the impact of host genetics on virological outcome |
| Q38256237 | Finding a cure for human immunodeficiency virus-1 infection |
| Q34043159 | Gene expression before HAART initiation predicts HIV-infected individuals at risk of poor CD4+ T-cell recovery |
| Q41762711 | HIV controllers maintain a population of highly efficient Th1 effector cells in contrast to patients treated in the long term. |
| Q36954950 | HIV rebounds from latently infected cells, rather than from continuing low-level replication |
| Q38675631 | HIV-1 Eradication: Early Trials (and Tribulations). |
| Q34889163 | HIV-1 infection induces strong production of IP-10 through TLR7/9-dependent pathways |
| Q36584830 | High-dimensional immunomonitoring models of HIV-1-specific CD8 T-cell responses accurately identify subjects achieving spontaneous viral control |
| Q90383564 | Host-HIV-1 Interactome: A Quest for Novel Therapeutic Intervention |
| Q45395724 | Human immunodeficiency virus (HIV)-specific T helper responses fail to predict CD4+ T cell decline following short-course treatment at primary HIV-1 infection |
| Q37333793 | Human immunodeficiency virus type 1 escapes from interleukin-2-producing CD4+ T-cell responses without high-frequency fixation of mutations |
| Q37199493 | Immune activation and collateral damage in AIDS pathogenesis. |
| Q33745356 | Immune escape mutations detected within HIV-1 epitopes associated with viral control during treatment interruption |
| Q40151311 | Immunogenicity of AGS-004 Dendritic Cell Therapy in Patients Treated During Acute HIV Infection |
| Q28469122 | Immunotherapy with canarypox vaccine and interleukin-2 for HIV-1 infection: termination of a randomized trial |
| Q42214247 | In-utero infection with HIV-1 associated with suppressed lymphoproliferative responses at birth. |
| Q39395758 | Lessons to be Learned from Natural Control of HIV - Future Directions, Therapeutic, and Preventive Implications |
| Q26795463 | Manipulation of the host protein acetylation network by human immunodeficiency virus type 1 |
| Q47574091 | Mathematical Models of HIV Latency |
| Q82029755 | Neurological sequelae of primary HIV infection |
| Q36263353 | No evidence of posttreatment control after early initiation of antiretroviral therapy |
| Q34220902 | No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial |
| Q34629153 | Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study |
| Q37613230 | Post-treatment control or treated controllers? Viral remission in treated and untreated primary HIV infection |
| Q60193733 | Prevention of SIVmac251 reservoir seeding in rhesus monkeys by early antiretroviral therapy |
| Q36975282 | Prevention of the sexual transmission of HIV-1: preparing for success |
| Q81433335 | Primary HIV-1 Infection: Diagnosis, Pathogenesis, and Treatment |
| Q43171945 | Primary HIV. |
| Q36223861 | Primary human immunodeficiency virus type 1 infection |
| Q40478218 | Primary human immunodeficiency virus type 1 infection: clinical, virological and immunological characteristics of 75 patients (1997-2003). |
| Q34447772 | Prolonged Control of an HIV Type 1 Escape Variant Following Treatment Interruption in an HLA-B*27-Positive Patient |
| Q39425108 | Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy |
| Q36047257 | Prolonged viral suppression without therapy in an HIV-1 seroconverter following early antiretroviral therapy and daily interleukin-2 |
| Q36951735 | Public T cell receptors confer high-avidity CD4 responses to HIV controllers |
| Q24796745 | Reconsidering early HIV treatment and supervised treatment interruptions |
| Q33332291 | Resisting immune exhaustion in HIV-1 infection. |
| Q30982732 | Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection |
| Q37098390 | Second European Round Table on the Future Management of HIV: 10-11 October 2014, Barcelona, Spain |
| Q35785225 | Selective depletion of high-avidity human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T cells after early HIV-1 infection |
| Q53244423 | State of HIV treatment: Results of the International Association of Physicians in AIDS Care surveys of HIV-positive patients and HIV-treating physicians in the United States. |
| Q35862206 | Structured Treatment Interruptions and Low Doses of IL-2 in Patients with Primary HIV Infection. Inflammatory, Virological and Immunological Outcomes |
| Q48505361 | The B-Cell Follicle in HIV Infection: Barrier to a Cure |
| Q33586581 | The detection and management of early HIV infection: a clinical and public health emergency |
| Q35623734 | The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals |
| Q22241890 | The spread, treatment, and prevention of HIV-1: evolution of a global pandemic |
| Q36280900 | Treatment during primary HIV infection does not lower viral set point but improves CD4 lymphocytes in an observational cohort |
| Q38116710 | Unravelling the mechanisms of durable control of HIV-1. |
| Q36026242 | Using mathematical modeling and control to develop structured treatment interruption strategies for HIV infection |
Search more.